These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

807 related articles for article (PubMed ID: 32651997)

  • 1. Tocilizumab for Treatment of Mechanically Ventilated Patients With COVID-19.
    Somers EC; Eschenauer GA; Troost JP; Golob JL; Gandhi TN; Wang L; Zhou N; Petty LA; Baang JH; Dillman NO; Frame D; Gregg KS; Kaul DR; Nagel J; Patel TS; Zhou S; Lauring AS; Hanauer DA; Martin E; Sharma P; Fung CM; Pogue JM
    Clin Infect Dis; 2021 Jul; 73(2):e445-e454. PubMed ID: 32651997
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tocilizumab for treatment of mechanically ventilated patients with COVID-19.
    Somers EC; Eschenauer GA; Troost JP; Golob JL; Gandhi TN; Wang L; Zhou N; Petty LA; Baang JH; Dillman NO; Frame D; Gregg KS; Kaul DR; Nagel J; Patel TS; Zhou S; Lauring AS; Hanauer DA; Martin E; Sharma P; Fung CM; Pogue JM
    medRxiv; 2020 Jun; ():. PubMed ID: 32577684
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tocilizumab in the treatment of critical COVID-19 pneumonia: A retrospective cohort study of mechanically ventilated patients.
    Fisher MJ; Marcos Raymundo LA; Monteforte M; Taub EM; Go R
    Int J Infect Dis; 2021 Feb; 103():536-539. PubMed ID: 33333252
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tocilizumab effectiveness in mechanically ventilated COVID-19 patients (T-MVC-19 Study): a multicenter real-world evidence.
    Mohzari YA; Alamer A; Alattas M; Alrashed AA; Alshehab NA; Alkhaldi TK; Alamer AA; Asdaq SMB; Aljefri D; Alajami HN; Alsowaida YS; Mathew M; AlMusawa MI; Alomar M; Alharbi RY; Khuwaja M; Bamogaddam RF; Alharthi AH; Faqihi AY; Alrumayyan BF; Alshareef A; Alhassan BM; Damfu NY; Alajmi GS; Albujaidy A; Alghalbi M; Alajlan SA; Abraham I; Almulhim AS
    Expert Rev Anti Infect Ther; 2022 Jul; 20(7):1037-1047. PubMed ID: 35209783
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association Between Early Treatment With Tocilizumab and Mortality Among Critically Ill Patients With COVID-19.
    Gupta S; Wang W; Hayek SS; Chan L; Mathews KS; Melamed ML; Brenner SK; Leonberg-Yoo A; Schenck EJ; Radbel J; Reiser J; Bansal A; Srivastava A; Zhou Y; Finkel D; Green A; Mallappallil M; Faugno AJ; Zhang J; Velez JCQ; Shaefi S; Parikh CR; Charytan DM; Athavale AM; Friedman AN; Redfern RE; Short SAP; Correa S; Pokharel KK; Admon AJ; Donnelly JP; Gershengorn HB; Douin DJ; Semler MW; Hernán MA; Leaf DE;
    JAMA Intern Med; 2021 Jan; 181(1):41-51. PubMed ID: 33080002
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tocilizumab use in patients with moderate to severe COVID-19: A retrospective cohort study.
    Chilimuri S; Sun H; Alemam A; Kang KS; Lao P; Mantri N; Schiller L; Sharabun M; Shehi E; Tejada J; Yugay A; Nayudu SK
    J Clin Pharm Ther; 2021 Apr; 46(2):440-446. PubMed ID: 33098139
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tocilizumab for Severe Worsening COVID-19 Pneumonia: a Propensity Score Analysis.
    Roumier M; Paule R; Vallée A; Rohmer J; Ballester M; Brun AL; Cerf C; Chabi ML; Chinet T; Colombier MA; Farfour E; Fourn E; Géri G; Khau D; Marroun I; Ponsoye M; Roux A; Salvator H; Schoindre Y; Si Larbi AG; Tchérakian C; Vasse M; Verrat A; Zuber B; Couderc LJ; Kahn JE; Groh M; Ackermann F;
    J Clin Immunol; 2021 Feb; 41(2):303-314. PubMed ID: 33188624
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tocilizumab Treatment for Cytokine Release Syndrome in Hospitalized Patients With Coronavirus Disease 2019: Survival and Clinical Outcomes.
    Price CC; Altice FL; Shyr Y; Koff A; Pischel L; Goshua G; Azar MM; Mcmanus D; Chen SC; Gleeson SE; Britto CJ; Azmy V; Kaman K; Gaston DC; Davis M; Burrello T; Harris Z; Villanueva MS; Aoun-Barakat L; Kang I; Seropian S; Chupp G; Bucala R; Kaminski N; Lee AI; LoRusso PM; Topal JE; Dela Cruz C; Malinis M
    Chest; 2020 Oct; 158(4):1397-1408. PubMed ID: 32553536
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of severely ill COVID-19 patients with anti-interleukin drugs (COV-AID): A structured summary of a study protocol for a randomised controlled trial.
    Maes B; Bosteels C; De Leeuw E; Declercq J; Van Damme K; Delporte A; Demeyere B; Vermeersch S; Vuylsteke M; Willaert J; Bollé L; Vanbiervliet Y; Decuypere J; Libeer F; Vandecasteele S; Peene I; Lambrecht B
    Trials; 2020 Jun; 21(1):468. PubMed ID: 32493441
    [TBL] [Abstract][Full Text] [Related]  

  • 10. "Ventilator-free days" composite outcome in patients with SARS-CoV-2 infection treated with tocilizumab: A retrospective competing risk analysis.
    Mady AF; Abdulrahman B; Mumtaz SA; Al-Odat MA; Kuhail A; Altoraifi R; Alshae R; Alharthy AM; Aletreby WT
    Heart Lung; 2022; 56():118-124. PubMed ID: 35839546
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Retrospective cohort study to assess the association between treatment with tocilizumab and mortality among mechanically ventilated patients with COVID-19.
    Skarbinski J; Liu L; Hong V; Amsden LB; Fireman BH; Yau VM; Incerti D; Qian L; Fischer H; Ackerson BK; Shaw SF; Tartof SY
    BMJ Open; 2022 Oct; 12(10):e060358. PubMed ID: 36316080
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of anti-interleukin drugs in patients with COVID-19 and signs of cytokine release syndrome (COV-AID): a factorial, randomised, controlled trial.
    Declercq J; Van Damme KFA; De Leeuw E; Maes B; Bosteels C; Tavernier SJ; De Buyser S; Colman R; Hites M; Verschelden G; Fivez T; Moerman F; Demedts IK; Dauby N; De Schryver N; Govaerts E; Vandecasteele SJ; Van Laethem J; Anguille S; van der Hilst J; Misset B; Slabbynck H; Wittebole X; Liénart F; Legrand C; Buyse M; Stevens D; Bauters F; Seys LJM; Aegerter H; Smole U; Bosteels V; Hoste L; Naesens L; Haerynck F; Vandekerckhove L; Depuydt P; van Braeckel E; Rottey S; Peene I; Van Der Straeten C; Hulstaert F; Lambrecht BN
    Lancet Respir Med; 2021 Dec; 9(12):1427-1438. PubMed ID: 34756178
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The COVIRL002 Trial-Tocilizumab for management of severe, non-critical COVID-19 infection: A structured summary of a study protocol for a randomised controlled trial.
    Cotter A; Wallace D; McCarthy C; Feeney E; O'Neill L; Stack J; McCarthy G; Hussain R; Alvarez Barco E; Doran P; Mallon P
    Trials; 2020 Sep; 21(1):758. PubMed ID: 32883328
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A prospective, randomised, double blind placebo-controlled trial to evaluate the efficacy and safety of tocilizumab in patients with severe COVID-19 pneumonia (TOC-COVID): A structured summary of a study protocol for a randomised controlled trial.
    Rilinger J; Kern WV; Duerschmied D; Supady A; Bode C; Staudacher DL; Wengenmayer T
    Trials; 2020 Jun; 21(1):470. PubMed ID: 32493514
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of Timing of Tocilizumab Use in Hospitalized Patients With SARS-CoV-2 Infection.
    Singh AK; Oks M; Husk G; Dechario SP; Mina B; Singh K; Kirschenbaum L; Carpati CM; Mahmoud O; Gabra NI; Ishikawa O; Altschultz E; Shah V; Mahajan A; Gautam A; Birnbaum B; Antonacci AC; Raoof S
    Respir Care; 2021 Dec; 66(12):1805-1814. PubMed ID: 34548407
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tocilizumab and steroid treatment in patients with COVID-19 pneumonia.
    Mikulska M; Nicolini LA; Signori A; Di Biagio A; Sepulcri C; Russo C; Dettori S; Berruti M; Sormani MP; Giacobbe DR; Vena A; De Maria A; Dentone C; Taramasso L; Mirabella M; Magnasco L; Mora S; Delfino E; Toscanini F; Balletto E; Alessandrini AI; Baldi F; Briano F; Camera M; Dodi F; Ferrazin A; Labate L; Mazzarello G; Pincino R; Portunato F; Tutino S; Barisione E; Bruzzone B; Orsi A; Schenone E; Rosseti N; Sasso E; Da Rin G; Pelosi P; Beltramini S; Giacomini M; Icardi G; Gratarola A; Bassetti M
    PLoS One; 2020; 15(8):e0237831. PubMed ID: 32817707
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tocilizumab in hospitalized patients with COVID-19: Clinical outcomes, inflammatory marker kinetics, and safety.
    Hill JA; Menon MP; Dhanireddy S; Wurfel MM; Green M; Jain R; Chan JD; Huang J; Bethune D; Turtle C; Johnston C; Xie H; Leisenring WM; Nina Kim H; Cheng GS
    J Med Virol; 2021 Apr; 93(4):2270-2280. PubMed ID: 33200828
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of Tocilizumab (Humanized Monoclonal Antibody) for Therapeutic Efficacy and Clinical Safety in Patients with Coronavirus Disease (COVID-19).
    Ullah S; Abid R; Haider S; Khuda F; Albadrani GM; Abdulhakim JA; Altyar AE; Abdel-Daim MM; Halimi SMA; Khalil AAK
    Medicina (Kaunas); 2022 Aug; 58(8):. PubMed ID: 36013543
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical characteristics and predictors of survival in adults with coronavirus disease 2019 receiving tocilizumab.
    Morrison AR; Johnson JM; Griebe KM; Jones MC; Stine JJ; Hencken LN; To L; Bianchini ML; Vahia AT; Swiderek J; Ramesh MS; Peters MA; Smith ZR
    J Autoimmun; 2020 Nov; 114():102512. PubMed ID: 32646770
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 41.